Incyte

-$0.61 (-0.78%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).

CEO
Herve Hoppenot
Employees
1,773
Headquarters
Wilmington, Delaware
Founded
1991

INCY Key Statistics

Market Cap
18.38B
Price-Earnings Ratio
35.99
Dividend Yield
—
Average Volume
1.47M
High Today
$79.81
Low Today
$77.22
Open Price
$78.18
Volume
1.65M
52 Week High
$101.96
52 Week Low
$75.52

INCY News

ReutersAug 3

Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Aug 3 (Reuters) - Eli Lilly and
BenzingaAug 2

A Preview Of Incyte's Earnings

Incyte (NASDAQ:INCY) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's
MarketWatchJul 29

Lilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monotherapy

By Chris Wack Eli Lilly & Co. and Incyte Corp. said the U.S. Food and Drug Administration has broadened the emergency use authorization for baricitinib to allo

INCY Earnings

-$2.86
-$1.49
-$0.13
$1.24
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
$0.75 per share
Actual
$0.80 per share
Replay Earnings Call
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure